{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:47:36Z","timestamp":1788389256583,"version":"build-2803163510"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Artificial intelligence (AI) can unveil novel personalized treatments based on drug screening and whole-exome sequencing experiments (WES). However, the concept of \u201cblack box\u201d in AI limits the potential of this approach to be translated into the clinical practice. In contrast, explainable AI (XAI) focuses on making AI results understandable to humans. Here, we present a novel XAI method -called multi-dimensional module optimization (MOM)- that associates drug screening with genetic events, while guaranteeing that predictions are interpretable and robust. We applied MOM to an acute myeloid leukemia (AML) cohort of 319\n                    <jats:italic>ex-vivo<\/jats:italic>\n                    tumor samples with 122 screened drugs and WES. MOM returned a therapeutic strategy based on the\n                    <jats:italic>FLT3<\/jats:italic>\n                    ,\n                    <jats:italic>CBF\u03b2-MYH11<\/jats:italic>\n                    , and\n                    <jats:italic>NRAS<\/jats:italic>\n                    status, which predicted AML patient response to Quizartinib, Trametinib, Selumetinib, and Crizotinib. We successfully validated the results in three different large-scale screening experiments. We believe that XAI will help healthcare providers and drug regulators better understand AI medical decisions.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.977358","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T01:34:51Z","timestamp":1664415291000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Explainable artificial intelligence for precision medicine in acute myeloid leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Marian","family":"Gimeno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edurne","family":"San Jos\u00e9-En\u00e9riz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Agirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Carazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nat"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Macarron","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.08.002","article-title":"The impact of oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre","volume":"50","author":"McVeigh","year":"2014","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1586\/erm.09.32","article-title":"MammaPrintTM 70-gene signature: Another milestone in personalized medical care for breast cancer patients","volume":"9","author":"Slodkowska","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-17673-9","article-title":"An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","article-title":"Predicting drug response and synergy using a deep learning model of human cancer cells","volume":"38","author":"Kuenzi","year":"2020","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine tumor board for acute myeloid leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s42256-020-00236-4","article-title":"Drug discovery with explainable artificial intelligence","volume":"2","author":"Jim\u00e9nez-Luna","year":"2020","journal-title":"Nat Mach Intell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41698-020-0122-1","article-title":"Machine learning approaches to drug response prediction: challenges and recent progress","volume":"4","author":"Adam","year":"2020","journal-title":"NPJ Precis Oncol"},{"key":"B10","volume-title":"Proposed Regulatory Framework for Modifications to Artificial Intelligence\/Machine Learning (AI\/ML)-Based Software as a Medical Device (SaMD)-Discussion Paper and Request for Feedback","year":"2019"},{"key":"B11","unstructured":"Artificial intelligence in medicine regulation | European medicines agency"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.06.004","article-title":"Human and machine: Better at pathology together","volume":"40","author":"Lazar","year":"2022","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2014.08.005","article-title":"New insights in AML biology from genomic analysis","volume":"51","author":"Perry","year":"2014","journal-title":"Semin Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ccr.2012.10.017","article-title":"SnapShot: Acute myeloid leukemia","volume":"22","author":"Zeisig","year":"2012","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2040620714532123","article-title":"The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond","volume":"5","author":"Wander","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"B16","author":"NIH","year":""},{"key":"B17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clml.2019.03.015","article-title":"Oral MEK 1\/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: A phase II study","volume":"19","author":"Ragon","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S171640","article-title":"Clinical use of FLT3 inhibitors in acute myeloid leukemia","volume":"11","author":"Sutamtewagul","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30208-9","article-title":"Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study","volume":"4","author":"Snijder","year":"2017","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3885","article-title":"Data-driven hypothesis weighting increases detection power in genome-scale multiple testing","volume":"13","author":"Ignatiadis","year":"2016","journal-title":"Nat Methods"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.3390\/cancers14133251","article-title":"Identifying lethal dependencies with HUGE predictive power","volume":"14","author":"Gimeno","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.2147\/CMAR.S169558","article-title":"The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials","volume":"10","author":"Guo","year":"2018","journal-title":"Cancer Manage Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.18632\/oncotarget.1457","article-title":"Targeting nucleocytoplasmic transport in cancer therapy","volume":"5","author":"Hill","year":"2014","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"12152","DOI":"10.1038\/s41598-020-69194-6","article-title":"Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.05.004","article-title":"Current status and new treatment approaches in TP53 mutated AML","volume":"32","author":"Hunter","year":"2019","journal-title":"Best Pract Res: Clin Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0096-1","article-title":"Trametinib: First global approval","volume":"73","author":"Wright","year":"2013","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.004","article-title":"Stepwise evolution of therapy resistance in AML","volume":"39","author":"Gui","year":"2021","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01331-x","article-title":"Selumetinib: First approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"w14207","DOI":"10.4414\/smw.2015.14207","article-title":"Targeting the RAS pathway by mitogen-activated protein kinase inhibitors","volume":"145","author":"Kiessling","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130487","article-title":"Cell type-specific effects of crizotinib in human acute myeloid leukemia with TP53 alterations","volume":"134","author":"Antony","year":"2019","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1038\/s41467-018-06916-5","article-title":"Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration","volume":"9","author":"McFarland","year":"2018","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat Genet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.cell.2017.01.013","article-title":"Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras","volume":"168","author":"Wang","year":"2017","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.7150\/ijms.46441","article-title":"Identification of the key genes and microRNAs in adult acute myeloid leukemia with FLT3 mutation by bioinformatics analysis","volume":"17","author":"Chen","year":"2020","journal-title":"Int J Med Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0817-4","article-title":"Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia","volume":"89","author":"Lucena-Araujo","year":"2010","journal-title":"Ann Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403625","article-title":"Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia","volume":"19","author":"Guti\u00e9rrez","year":"2005","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.1038\/s41467-021-26420-7","article-title":"Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-012773","article-title":"Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability","volume":"108","author":"Wunderlich","year":"2006","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0448-2","article-title":"Transforming growth factor (TGF)-\u03b2 pathway as a therapeutic target in lower risk myelodysplastic syndromes","volume":"33","author":"Bewersdorf","year":"2019","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-860890","article-title":"SKI controls MDS-associated chronic TGF-\u03b2 signaling, aberrant splicing, and stem cell fitness","volume":"132","author":"Muench","year":"2018","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1021","article-title":"Improving AML classification using splicing signatures","volume":"26","author":"Bowman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0315-9","article-title":"Aberrant splicing and drug resistance in AML","volume":"9","author":"De Necochea-Campion","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41467-020-20848-z","article-title":"RUNX1\/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia","volume":"12","author":"Grinev","year":"2021","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3756","article-title":"Precision oncology for acute myeloid leukemia using a knowledge bank approach","volume":"49","author":"Gerstung","year":"2017","journal-title":"Nat Genet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1109\/RBME.2020.3007816","article-title":"Machine learning for clinical outcome prediction","volume":"14","author":"Shamout","year":"2021","journal-title":"IEEE Rev Biomed Eng"},{"key":"B55","article-title":"Interpretable Machine Learning in Healthcare","volume-title":"Proceedings of the 2018 ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (BCB '18)","author":"Ahmad","year":"2018"},{"key":"B56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/bib\/bbaa032","article-title":"Machine learning-based analysis of multi-omics data on the cloud for investigating gene regulations","volume":"22","author":"Oh","year":"2021","journal-title":"Brief Bioinform"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009933","article-title":"Emerging therapies for inv(16) AML","volume":"137","author":"Surapally","year":"2021","journal-title":"Blood"},{"key":"B58","first-page":"91","article-title":"Trametinib (GSK1120212)","volume-title":"Recent results in cancer research","author":"Zeiser","year":"2018"},{"key":"B59","article-title":"Impute: Imputation for microarray data","volume":"17","author":"Hastie","year":"2001","journal-title":"Bioinformatics"},{"key":"B60","article-title":"Trametinib (GSK1120212)","volume-title":"Recent results in cancer research","author":"Zeiser","year":"2018"},{"key":"B61","article-title":"Impute: Imputation for microarray data","volume":"17","author":"Hastie","year":"2001","journal-title":"Bioinformatics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.977358\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T01:35:05Z","timestamp":1664415305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.977358\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2022.977358"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.977358","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"977358"}}